HRMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Harmony Biosciences Holdings Inc (HRMY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown solid revenue and income growth in the latest quarter, the stock appears range-bound with limited near-term catalysts. Additionally, technical indicators are mixed, and there is no strong proprietary trading signal to suggest immediate action. Holding off for now may be prudent.
The MACD is negative and expanding (-0.0809), indicating bearish momentum. RSI is neutral at 35.202, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels show the stock is trading near support (S1: 35.92). Overall, the technical outlook is mixed with no clear upward momentum.
Revenue and net income have shown strong YoY growth in the latest quarter.
Gross margin has slightly decreased (-2.49% YoY). The stock has a 60% chance of declining in the next week (-2.34%) and no significant news or events to drive immediate upside.
In Q3 2025, revenue increased by 28.71% YoY to $239.46M, net income rose by 10.35% YoY to $50.87M, and EPS grew by 10.13% YoY to $0.87. However, gross margin dropped slightly to 75.09%, down 2.49% YoY.
UBS downgraded the stock to Neutral with a price target of $46, up from $43, citing range-bound performance until after 2027. Truist maintains a Buy rating but lowered its price target to $45 from $48, reflecting updated models but unchanged fundamental views.
